Pulling SEC filings + quote and writing the call…

AXCELIS TECHNOLOGIES INC
Next earnings Aug 3, 2026 · consensus $0.91 EPS, $209M rev
Last earnings -7.2% on 2026-05-07
Ion-implant semicap leader in a cyclical trough — pristine balance sheet and buybacks, but full valuation and heavy China/export-control risk.
Axcelis is a focused leader in ion-implantation equipment for semiconductor manufacturing, with particular strength in the implant-intensive power-device segment (55% of 2025 system shipment value). FY2025 was a cyclical down-year: revenue fell 17.6% to $839M (systems revenue dropped to $571M from $782.6M), operating income fell 43.4% to $119M, and diluted EPS dropped 38.2% to $3.80. Management frames this squarely as industry cyclicality — 'the semiconductor capital equipment industry is subject to cyclical swings in capital spending' — and notes its 'established cost structure does not vary significantly with changes in volume,' which is why margins fall hard when revenue declines.
Sources: SEC EDGAR (CIK 0001113232, latest 10-Q filed 2026-05-08) · analysis by claude-code · as of 6/21/2026, 8:55:57 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $662M | $920M | $1.13B | $1.02B | $839M |
| Gross profit | $286M | $402M | $491M | $455M | $377M |
| Operating income | $127M | $212M | $266M | $211M | $119M |
| Net income | — | — | $246M | $201M | $120M |
| Diluted EPS | $2.88 | $5.46 | $7.43 | $6.15 | $3.80 |
| Net margin | — | — | 21.8% | 19.7% | 14.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1046 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Last 90 days: 0 open-market buys · 6 sales
| 2026-06-16 | Ryzhik David SVP Interim CFO | Tax | 76.00 @ $176.85 | $13.4K |
| 2026-06-15 | Blumenstock Gerald M EVP, Research, Dev. & Eng. | Tax | 506.00 @ $191.60 | $96.9K |
| 2026-06-03 | Sayiner Necip Director | Sell | 1.59K @ $157.44 | $250K |
| 2026-06-02 | Mahoney Robert John EVP Global Operations | Sell | 1.16K @ $155.24 | $179K |
| 2026-05-27 | Sutton Todd VP Corporate Controller | Sell | 2.00K @ $159.99 | $320K |
| 2026-05-22 | St Dennis Thomas Director | Sell | 900.00 @ $155.37 | $140K |
| 2026-05-22 | Evans Eileen EVP, General Counsel and Sec'y | Sell | 926.00 @ $155.51 | $144K |
| 2026-05-21 | Blumenstock Gerald M EVP, Research, Dev. & Eng. | Sell | 1.16K @ $152.70 | $177K |